Results 41 to 50 of about 4,266 (228)

The Real‐World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study

JBMR Plus, 2022
Excluding clinical trials, there is limited evidence on the effect of 12 months of romosozumab treatment on bone mineral density (BMD) increase in real‐world clinical practice because its use has only been approved recently.
Hiroyuki Inose, Akane Ariga, Takayuki Motoyoshi, Kazuyuki Fukushima, Shoji Tomizawa, Tsuyoshi Kato, Kunihiko Takahashi, Toshitaka Yoshii, Atsushi Okawa   +8 more
doaj   +1 more source

Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study

Osteoporosis and Sarcopenia, 2021
Objectives: To investigate effects of romosozumab treatment on disease activity and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) and severe osteoporosis in comparison with effects of denosumab treatment.
Takeshi Mochizuki, Koichiro Yano, Katsunori Ikari, Ken Okazaki   +3 more
doaj   +1 more source

▼Romosozumab for osteoporosis

Drug and Therapeutics Bulletin, 2021
Abstract Generic name: Romosozumab Brand name: Evenity Formulation: 105 mg solution for injection in a pre-filled pen Market Authorisation holder: UCB Pharma Limited Indication ...
openaire   +3 more sources

Successful treatment of humeral shaft nonunion with romosozumab: A case report

Trauma Case Reports, 2022
Romosozumab is a humanized monoclonal anti-sclerostin antibody (Scl-Ab) that binds and inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption.
Sang Yang Lee, Keikichi Kawasaki, Katsunori Inagaki   +2 more
doaj   +1 more source

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report

Bone Reports, 2020
Discontinuation of denosumab is associated with the increase of bone turnover markers to above-baseline levels (so-called rebound in bone turnover) and rapid bone loss.
Masafumi Kashii, Kosuke Ebina, Kazuma Kitaguchi, Hideki Yoshikawa   +3 more
doaj   +1 more source

Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials

Osteoporosis and Sarcopenia, 2020
Objectives: Falls are the well-known risk factor for osteoporotic fractures and some medications can increase the risk of falls. Therefore, the aim of our study is to evaluate the effect of romosozumab on risk of falls in postmenopausal women.
Luis Möckel, Matthias Bartneck, Christina Möckel   +2 more
doaj   +1 more source

Denosumab versus romosozumab for postmenopausal osteoporosis treatment

Scientific Reports, 2021
Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular-targeted drugs for postmenopausal osteoporosis treatment.
Tomonori Kobayakawa, Akiko Miyazaki, Makoto Saito, Takako Suzuki, Jun Takahashi, Yukio Nakamura   +5 more
doaj   +1 more source

Increase in serum DKK1 levels attenuates the anabolic response to romosozumab in postmenopausal osteoporosis. [PDF]

J Bone Miner Res
Romosozumab is a monoclonal antibody against sclerostin that initially exhibits potent anabolic effects in treating osteoporosis. However, its efficacy diminishes after 6 mo, with bone formation markers declining despite continued therapy.
Adami G, Montanari F, Fassio A, Pollastri F, Piccinelli A, Benini C, Pasetto E, Tugnolli M, Gatti D, Rossini M, Viapiana O.   +10 more
europepmc   +2 more sources

Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives

International Journal of Women's Health, 2022
Sian Yik Lim,1,2 Marcy B Bolster3 1Hawaii Pacific Health Medical Group, Honolulu, HI, USA; 2Department of Family Medicine, John E Burns School of Medicine, University of Hawaii, Honolulu, HI, USA; 3Division of Rheumatology, Allergy, and Immunology ...
Lim SY, Bolster MB
doaj  

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. [PDF]

, 2018
Romosozumab is a bone-forming agent with a dual effect of increasing bone formation and decreasing bone resorption. In FRActure study in postmenopausal woMen with ostEoporosis (FRAME), postmenopausal women with osteoporosis received romosozumab 210 mg s ...
Cesar Libanati, A. Khan, Lippuner, Kurt, Ferrari, Serge, Grauer, Andreas, Khan, Aliya, F. Cosman, Lane, Nancy E, D.B. Crittenden, T. Matsumoto, Toshio Matsumoto, Aliya Khan, Cosman, Felicia, C. Libanati, N.E. Lane, A. Grauer, K. Lippuner, Daria B Crittenden, Cassandra E Milmont, C.E. Milmont, Milmont, Cassandra E, Kurt Lippuner, Serge Ferrari, Ferrari, Serge Livio, Matsumoto, Toshio, Crittenden, Daria B, Felicia Cosman, Andreas Grauer, Libanati, Cesar, Nancy E Lane, S. Ferrari   +30 more
core   +1 more source